- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- delandistrogene moxeparvovec, placebo
- Genetic
- Lead sponsor
- Sarepta Therapeutics, Inc.
- Industry
- Eligibility
- 4 Years to 7 Years · Male only
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 23
- States / cities
- Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 20 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1825–1848
of 9,381
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Asthma
- Interventions
- GP MDI 28.8 μg, GP MDI 14.4 μg, GP MDI 7.2 μg, Placebo MDI, Spiriva Respimat 2.5 μg
- Drug
- Lead sponsor
- Pearl Therapeutics, Inc.
- Industry
- Eligibility
- 12 Years to 80 Years
- Enrollment
- 1,077 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 232
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Guntersville, Alabama + 188 more
- Conditions
- Neoplasms, Cancer
- Interventions
- Not listed
- Lead sponsor
- GRAIL, Inc.
- Industry
- Eligibility
- 20 Years and older
- Enrollment
- 15,254 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2024
- U.S. locations
- 139
- States / cities
- Daphne, Alabama • Mobile, Alabama • Phoenix, Arizona + 105 more
- Conditions
- Spondyloarthritis
- Interventions
- Ixekizumab, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 316 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 27
- States / cities
- Phoenix, Arizona • Escondido, California • Huntington Beach, California + 24 more
- Conditions
- Aortic Valve Regurgitation, Aortic Valve Disease Mixed
- Interventions
- J-Valve Transfemoral (TF) System
- Device
- Lead sponsor
- JC Medical, Inc., an affiliate of Edwards Lifesciences LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 194 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 35
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 27 more
- Conditions
- Melanoma (Skin), Metastatic Cancer
- Interventions
- sargramostim
- Biological
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2012
- U.S. locations
- 87
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Aurora, Illinois + 54 more
- Conditions
- Advanced Cancer
- Interventions
- CDX-0158 (formerly known as KTN-0158)
- Biological
- Lead sponsor
- Celldex Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Portland, Oregon • Nashville, Tennessee
- Conditions
- Diabetic Macular Edema
- Interventions
- KSI-301, Aflibercept, Sham Procedure
- Drug · Other
- Lead sponsor
- Kodiak Sciences Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 460 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 48
- States / cities
- La Jolla, California • Redlands, California • Santa Maria, California + 44 more
- Conditions
- Deep Vein Thrombosis, Venous Stasis, Venous Insufficiency, Venous Leg Ulcer, Venous Reflux, Post Thrombotic Syndrome
- Interventions
- Stents
- Device
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 29
- States / cities
- Orange, California • San Francisco, California • New Haven, Connecticut + 23 more
- Conditions
- Low Back Pain
- Interventions
- Tanezumab 20 mg, Tanezumab 10 mg
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 849 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 149
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Hueytown, Alabama + 99 more
- Conditions
- Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Hodgkin Disease, Lymphoma, Lymphoma, B-Cell, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Melanoma, Neoplasm Metastasis, Neoplasms, Head and Neck, Neoplasms, Squamous Cell, Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer Metastatic, Non-small Cell Carcinoma, Squamous Cell Cancer, Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Neoplasm, Lymphoma, Non-Hodgkin, Pancreatic Adenocarcinoma
- Interventions
- Intravenous (IV) SEA-CD40, Pembrolizumab, Subcutaneous (SC) SEA-CD40, Gemcitabine, Nab-paclitaxel
- Drug
- Lead sponsor
- Seagen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 159 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 15 more
- Conditions
- Cystic Fibrosis
- Interventions
- ELX/TEZ/IVA, IVA
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 2 Years to 5 Years
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 13
- States / cities
- Tucson, Arizona • Palo Alto, California • Aurora, Colorado + 10 more
- Conditions
- Legg Calve Perthes Disease
- Interventions
- Osteotomy + Long Term Non-Weight Bearing, Osteotomy + Short Term Non-Weight Bearing, Nonoperative Observation, Multiple Epiphyseal Drilling
- Procedure
- Lead sponsor
- Texas Scottish Rite Hospital for Children
- Other
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 1,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2032
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Diego, California + 23 more
- Conditions
- Actinic Keratosis
- Interventions
- Imiquimod Cream, 3.75%, Zyclara®, Vehicle of Test Product
- Drug · Other
- Lead sponsor
- Teva Pharmaceuticals USA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 589 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 23
- States / cities
- Tucson, Arizona • Encino, California • Los Angeles, California + 20 more
- Conditions
- PARKINSON DISEASE (Disorder), Parkinson, Parkinson's Disease and Parkinsonism, Parkinson Disease
- Interventions
- No Intervention: Observational Cohort
- Diagnostic Test
- Lead sponsor
- CND Life Sciences
- Other
- Eligibility
- 40 Years to 99 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)
- Interventions
- Zanzalintinib, Everolimus
- Drug
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 440 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 38 more
- Conditions
- Aortic Valve Stenosis, Mitral Regurgitation
- Interventions
- Automated alert
- Behavioral
- Lead sponsor
- Tempus AI
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 6
- States / cities
- Kansas City, Missouri • Columbus, Ohio • Lima, Ohio + 3 more
- Conditions
- Measurements of Patients Using OCT Before and After LASIK
- Interventions
- Not listed
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Low Back Pain
- Interventions
- Tanezumab 20 mg IV, Placebo for naproxen, Tanezumab 10 mg IV, Tanezumab 5 mg IV, Placebo for tanezumab, Naproxen
- Biological · Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,359 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 135
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Hueytown, Alabama + 101 more
- Conditions
- Cardiomyopathy, Coronary Artery Disease, Congestive Heart Failure, Myocardial Infarction
- Interventions
- Implantable Cardioverter Defibrillator, Optimal Medical Therapy
- Device · Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 70 Years and older
- Enrollment
- 167 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 5
- States / cities
- Washington D.C., District of Columbia • Gainesville, Florida • Minneapolis, Minnesota + 2 more
- Conditions
- Bladder Cancer
- Interventions
- Atezolizumab, Bacille Calmette-Guérin
- Drug · Biological
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 8
- States / cities
- Stanford, California • Chicago, Illinois • Baltimore, Maryland + 5 more
- Conditions
- Safety Issues, Tolerability, Pharmacokinetics
- Interventions
- IPG7236
- Drug
- Lead sponsor
- Nanjing Immunophage Biotech Co., Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 2
- States / cities
- Portland, Oregon • Austin, Texas
- Conditions
- Pancreatic Ductal Adenocarcinoma
- Interventions
- Navlimetostat, Gemcitabine, Nab-paclitaxel, Placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 470 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 48
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Springdale, Arkansas + 38 more
- Conditions
- Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis
- Interventions
- Rocatinlimab, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 54 Years
- Enrollment
- 221 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 72
- States / cities
- Scottsdale, Arizona • Tempe, Arizona • Little Rock, Arkansas + 61 more